This study reports the use of chitosan microcapsules for daunorubicin delivery via an oral route. The potential oral delivery of the daunorubicin/chitosan microcapsules was examined using an in vivo athymic nude mice xenograft model with Non-Hodgkin's lymphoma cells. Microencapsulated daunorubicin could be administered orally with tumour growth inhibition activity.